On October 21, 2021 AskGene, a biotechnology company developing next-generation cytokine therapeutics, and novel bi-specific antibodies to treat cancer and other diseases, and ATUM, a California-based bioengineering company, reported the successful Investigational New Drug (IND) filing in China for AskGene’s new antibody drug (Press release, AskGene Pharmaceuticals, OCT 21, 2021, View Source [SID1234591727]). The antibody was produced using the Leap-In Transposase technology pioneered by ATUM and represents the tenth successful IND clearance globally using this platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are encouraged to see how fast the Leap-In Transposase technology has been broadly accepted in the marketplace. We started licensing the platform four years ago and already see the approval of ten successful IND filings," said Oren Beske, Ph.D., Vice President of Business and Strategy at ATUM. "AskGene Pharma was one of the earliest adopters of the Leap-In Transposase technology and we are excited to see how fast they have reached IND filing status."
The Leap-In Transposase technology enables rapid, stable, and robust manufacturing of mammalian cell lines for the production of commercial-grade protein pharmaceuticals. The technology has been evaluated and accepted by multiple independent IND authorizing entities, including the Chinese National Medical Products Administration (NMPA), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA).
"AskGene is committed to rapidly bringing safe and effective medicines to patients through the use of innovative technologies. We are very pleased to cooperate with ATUM to support us in developing the promising antibodies and next-generation cytokine therapeutics to benefit patients," said AskGene’s CEO, Jeff Lu, Ph.D. "The exceptional genetic stability of the cell lines developed using ATUM’s Leap-in Transposase technology was an important aspect of our successful IND filing and provided an incredibly efficient solution for cell line design and manufacturing."
For more information about the Leap-In Transposase technology, please visit www.atum.bio/pipeline/cld.